Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.49 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 4/20 | 0.42 |
| ▸ | VEGFA | P15692 | 3/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485021 | 0.90 | CHEK2 (0.47) | EGLN1EGLN3ALOX5SLC22A12CHEK1 | |
| SCHEMBL3485422 | 0.89 | EGLN1 (0.44) | EGLN1EGLN3ALOX5CHEK1CHEK2 | |
| SCHEMBL3485378 | 0.89 | ALOX5 (0.43) | EGLN1EGLN3ALOX5SLC22A12CHEK1 | |
| SCHEMBL3485534 | 0.89 | ALOX5 (0.42) | EGLN1EGLN3ALOX5SLC22A12CHEK1 | |
| SCHEMBL3484922 | 0.86 | EGLN1 (0.44) | EGLN1EGLN3ALOX5CHEK1CHEK2 | |
| SCHEMBL3485031 | 0.80 | TSHR (0.49) | EGLN1EGLN3ALOX5CHEK1CHEK2 | |
| SCHEMBL1921887 | 0.80 | EGLN1 (0.65) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL3485876 | 0.80 | EGLN1 (0.67) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL14331238 | 0.79 | EGLN1 (0.71) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL15164150 | 0.79 | EGLN1 (0.54) | EGLN1EGLN3FLT1VEGFAFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885ALOX5 624/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885ALOX5 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.